Genzyme Wins Cholesterol Drug Deal
18221
Genzyme has agreed to pay at least $325 million to win the hotly contested rights to a potentially powerful cholesterol-lowering drug.
688289
The Food and Drug Administration approved Clolar, Genzyme Corp.'s new drug for patients under 21 with acute lymphocytic leukemia. An advisory panel on Dec. 1 recommended the drug be approved. Clolar was developed by Ilex Oncology Inc., the Texas firm Cambridge-based Genzyme acquired last week in a $1 billion stock transaction. The FDA panel recommended that more studies be done ...
438918
Duke researchers recently uncovered that an immediate and aggressive dosing regime of statins, cholesterol-lowering drugs, successfully reduces the future risk of heart attacks.
723413
Pfizer Inc., the world's largest drugmaker, said Wednesday it won a court ruling in the Netherlands preventing Indian rival Ranbaxy Laboratories Ltd. from releasing a generic version of the company's cholesterol-reducing drug Lipitor.
646040
A heart treatment from Canadian   biotech firm Vasogen Inc., which failed a key clinical trial   hurdle in June, still helped more than 70 percent of patients,   researchers said on Sunday.
549383
THE REGION Genzyme Corp. , maker of enzyme therapies for rare diseases, had a loss in the fourth quarter on acquisition costs but expects higher sales in 2007. The net loss was $268.2 million, or $1.02 a share, versus net income of $106.6 million, or 39 cents, a year earlier, the Cambridge company said. Profit excluding some costs beat analyst ...
28028
Genzyme Corp.&#39;s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug
246930
Biotechnology company Genzyme Corp  reported a fourth-quarter profit on Wednesday, reversing a year-earlier loss, as sales of its drugs for rare diseases increased.
232342
Genzyme (GENZ :Nasdaq - news - research) shares rose early Wednesday after US regulators approved its leukemia drug for children. The Food and Drug Administration Tuesday approved the drug Clolar, an intravenous
56545
Piper Jaffray maintained an &quot;outperform&quot; rating and $70 target price on Genzyme (nasdaq: GENZ - news - people ), citing the FDA&#39;s approval of Clolar for the treatment of pediatric acute lymphocytic leukemia (ALL) in patients between 1 and 21 years who
494130
Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).
536259
Genzyme Corp.'s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug Administration recommended the agency approve Ilex's experimental cancer treatment for children with certain types of leukemia.
654609
Genzyme and Millenium vie to purchase the Canadian biotech.
301333
NEW YORK  - Genzyme Corp. announced  Wednesday that its drug Clolar has been approved by the U.S.  Food and Drug Administration (FDA) for the treatment of  children with difficult or relapsed acute lymphoblastic  leukemia (ALL).
557373
Cambridge Antibody Technology Group Plc  has won a UK court case to get a bigger slice of sales of a  potential blockbuster arthritis medicine, sending its shares  more than 25 percent higher on Monday.
249246
Genentech and Biogen Idec's drug shows positive results against multiple sclerosis.
490579
Biotechnology company Genzyme Corp. said one of its experimental treatments for pain associated with osteoarthritis of the knee works no better than traditional steroids. The therapy, hylastan, is one of several viscosupplements -- injectable substances that lubricate the joints -- that Genzyme is developing to succeed its existing product, Synvisc.